[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589866":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":25,"centralContacts":26,"locations":35,"responsibleParty":57,"collaborators":61,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":25,"eligibilityCriteria":74,"healthyVolunteers":71,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":25,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":25,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Prospective","EXPERIMENTAL","To establish ex-vivo translational models of MB, we will develop patient-derived organoids (PDOs) from primary surgical biopsies of patients",[13],"Drug: CDK4\u002F6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib)",{"label":15,"type":10,"description":11,"interventionNames":16},"Retrospective",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","CDK4\u002F6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib)","Evaluation of the response to CDK4\u002F6 inhibitors (Palbociclib, Ribociclib, Abemaciclib) on selected Medulloblastoma (MB) patient-derived organoids (PDOs).",[9,15],[24],"We will then evaluate the effects of CDK4\u002F6 inhibitors on the selected MB PDOs.",null,[27,32],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"GIANPIERO TAMBURRINI, MD","CONTACT","3349468776","gianpiero.tamburrini@unicatt.it",{"name":33,"role":29,"phone":25,"phoneExt":25,"email":34},"MARIA CONCETTA GELOSO, PHD","mariaconcetta.geloso@unicatt.it",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Fondazione Policlinico Gemelli Irccs","RECRUITING","Roma","ROMA","00151","Italy","IT",{"type":45,"coordinates":46},"Point",[47,48],11.10642,44.99364,{"lat":48,"lon":47},[51,53],{"name":28,"role":29,"phone":52,"phoneExt":25,"email":31},"00393349468776",{"name":54,"role":29,"phone":55,"phoneExt":25,"email":56},"CONCETTA GELOSO, PHD","00393396269606","MARIACONCETTA.GELOSO@UNICATT.IT",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Tamburrini Gianpiero","Prof.",[62,64,66],{"name":63,"class":6},"University of Rome Tor Vergata",{"name":65,"class":6},"Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello",{"name":67,"class":68},"Università degli Studi di Enna Kore","UNKNOWN","100589866","early-phase-1-novel-molecular-targets-and-innovative-therapeutic-perspective-in-medulloblastoma-100589866",false,"NCT06959979","Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma","Inclusion Criteria:\n\n* All patients affected by Medulloblastoma operated on at the Pediatric Neurosurgery Unit during their pediatric age will be elected to take part to the study","ALL","0 Years","18 Years",{"count":79,"type":80},60,"ESTIMATED","INTERVENTIONAL",[83],"EARLY_PHASE1","Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therapeutic advances, neurotoxicity from standard treatments (resection, radiotherapy, chemotherapy) and the need for long-term care remain challenges. CDK4\u002F6 inhibitors (palbociclib, ribociclib, abemaciclib), approved for breast cancer, show potential in other tumors, but their efficacy in MB is unclear. Treatment resistance is a concern. This project aims to identify genetic markers of sensitivity to CDK4\u002F6 inhibitors in MB, to improve therapies and overcome resistance.",[86],"Medulloblastoma, Childhood","2025-04-28",{"date":89,"type":90},"2025-05-07","ACTUAL",{"date":92,"type":90},"2024-11-25",{"date":94,"type":80},"2026-08-31",{"name":5,"class":6},1]